Nitroxyl Technology

Cardioxyl has developed industry leading expertise in nitroxyl (HNO) chemistry and biology, and is employing its nitroxyl chemistry platform to discover and develop novel, proprietary therapeutics targeting cardiovascular disease.
Read More

CXL-1020

Cardioxyl's lead drug candidate, CXL-1020, is in clinical development for acute decompensated heart failure, the most common cause of hospitalization for patients older than 65 years of age. CXL-1020 has been evaluated in a multi-center Phase I/IIa clinical trial, and Cardioxyl is preparing to initiate a Phase IIa trial with the drug candidate.
Read More